A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) (TroFuse-031)

Complete Title: A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
Trial Phase: III
Investigator: Grivas, Petros

Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies.

Look up Trial at NIH
Keywords:
  • Bladder Cancer
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Checklist icon

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Patient Guide to Clinical Trials

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.

Request an Appointment